0001683168-18-003709.txt : 20181214 0001683168-18-003709.hdr.sgml : 20181214 20181214163324 ACCESSION NUMBER: 0001683168-18-003709 CONFORMED SUBMISSION TYPE: 1-A/A PUBLIC DOCUMENT COUNT: 3 FILED AS OF DATE: 20181214 DATE AS OF CHANGE: 20181214 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Global Cancer Technology, Inc. CENTRAL INDEX KEY: 0001743261 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 461785241 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 1-A/A SEC ACT: 1933 Act SEC FILE NUMBER: 024-10909 FILM NUMBER: 181235972 BUSINESS ADDRESS: STREET 1: 16776 BERNARDO CENTER DRIVE, SUITE 203 CITY: SAN DIEGO STATE: CA ZIP: 92128 BUSINESS PHONE: 8584516173 MAIL ADDRESS: STREET 1: 16776 BERNARDO CENTER DRIVE, SUITE 203 CITY: SAN DIEGO STATE: CA ZIP: 92128 1-A/A 1 primary_doc.xml 1-A/A LIVE 0001743261 XXXXXXXX 024-10909 true Global Cancer Technology, Inc. NV 2017 0001743261 3841 46-1785241 1 0 16776 BERNARDO CENTER DRIVE, SUITE 203 SAN DIEGO CA 92128 619-818-2411 Ronald N. Vance Other 32223.00 0.00 32223.00 0.00 33271.00 322677.00 0.00 322677.00 -289406.00 33271.00 0.00 0.00 0.00 -185556.00 0.02 0.02 Ankit Consulting Inc. Common Stock 11551200 000000N/A N/A None 0 000000N/A N/A Convertible Promissory Notes 202500 000000N/A None true true true Tier2 Audited Equity (common or preferred stock) Y N N Y N N 1832533 11551200 3.0000 4000000.00 1497600.00 0.00 0.00 5497600.00 Ankit Consulting Inc. 20000.00 Pearson, Butler, & Carson PLLC 25000.00 3955000.00 true AL AK AZ AR CA CO CT DE FL GA HI ID IL IN IA KS KY LA ME MD MA MI MN MS MO MT NE NV NH NJ NM NY NC ND OH OK OR PA RI SC SD TN TX UT VT VA WA WV WI WY DC PR Global Cancer Technology, Inc. Common Stock 711700 0 207,525 (Common Stock) based on cash payments or negotiated exchange for services Global Cancer Technology, Inc. Convertible Promissory Notes 202500 0 $202,500 for Convertible Promissory Notes See Exhibit 15.2 filed herewith PART II AND III 2 globalcancer_1a-a2.htm PART II AND III

EXPLANATORY NOTE

 

In accordance with Rule 252(f)(iii) promulgated by the Securities and Exchange Commission under the Securities Act of 1933, as amended, Global Cancer Technology, Inc. is amending its Form 1/A solely to include a current auditor consent in Exhibit 11.1.

 

 

 

 

 

 

   

 

 

PART III

 

EXHIBITS TO OFFERING STATEMENT

 

    Incorporated by Reference  
Exhibit Number Exhibit Description Form File No. Exhibit Filing Date Filed
Herewith
2.1 Plan of Conversion dated January ___, 2017 DOS 367-00167 2.1 9/7/18  
2.2 Articles of Incorporation DOS 367-00167 2.2 9/7/18  
2.3 Nevada Articles of Conversion DOS 367-00167 2.3 9/7/18  
2.4 Texas Certificate of Conversion DOS 367-00167 2.4 9/7/18  
2.5 Current Bylaws 1-A 024-10909 2.5 10/15/18  
3.1 2018 Stock Incentive Plan 1-A 024-10909 3.1 10/15/18  
4.1 Subscription Agreement 1-A 024-10909 4.1 10/15/18  
6.1 CEO Employment Agreement dated May 1, 2018 DOS 367-00167 6.1 9/7/18  
6.2 NanoMed Tracking Shareholder Agreement dated June 26, 2017 1-A 024-10909 6.2 10/15/18  
6.3 MCW Pharmaceuticals Shareholder Agreement dated May 17, 2018 1-A 024-10909 6.3 10/15/18  
6.4 Sponsored Research Agreement with the University of Washington as of August 21, 2018 DOS 367-00167 6.4 9/7/18  
6.5 License Agreement dated October 13, 2016 with UCSD 1-A 024-10909 6.5 10/15/18  
6.6 License Agreement dated November 18, 2016 with UCSD 1-A 024-10909 6.6 10/15/18  
6.7 License Agreement dated March 18, 2018 with University of Washington 1-A 024-10909 6.7 10/15/18  
6.8 License Agreement dated October 1, 2017 with American Radiosurgery 1-A 024-10909 6.8 10/15/18  
11.1 Consent of Ankit Consulting Inc., independent registered public accounting firm          X
12.1 Opinion re Legality of Shares 1-A/A 024-10909 11.2 11/7/18  
15.1 Code of Ethics DOS 367-00167 15.1 9/7/18  
15.2 Part I - Item 6 explanation DOS 367-00167 15.2 9/7/18  

 

 

 

 

 

 

 

 III-1 

 

 

SIGNATURES

 

Pursuant to the requirements of Regulation A, the issuer certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form 1-A and has duly caused this offering statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Diego, California, on December 14, 2018.

 

  GLOBAL CANCER TECHNOLOGY, INC.
   
   
  By: /s/ John Clark
  John Clark, CEO

 

 

This offering statement has been signed by the following persons in the capacities and on the dates indicated.

 

Name   Capacity   Date
/s/ John Clark   Sole Director and CEO (Principal Executive, Financial & Accounting Officer)   December 14, 2018

 

 

 

 

 

 

 

 

 

 

 

 

 

 III-2 

 EX1A-11 CONSENT 3 globalcancer_1aa2-1101.htm EXHIBIT 11.1 CONSENT

Exhibit 11.1

 

Ankit Consulting Services, Inc.

 

 

 

30211 Avenida de Las Banderas, Suite # 200, Rancho Santa Margarita, CA 92688

Phone: 949-683-3034, Facsimile: 949-271-4737

 

 

Consent of Independent Registered Public Accounting Firm

 

We consent to the inclusion, in this Registration A Offering Statement as a part, of the report dated August 29, 2018 relative to the financial statements of Global Cancer Technologies, Inc. and Subsidiaries as of December 31, 2017 and 2016 and for the years ended December 31, 2017 and 2016.

 

We also consent to the reference to my firm under the caption "Experts" in such Offering Statement.

 

/s/Ankit Consulting Services, Inc.

Ankit Consulting Services, Inc.

Certified Public Accountants Rancho Santa Margarita, CA

December 14, 2018